COV Stock Overview
A medical diagnostics and devices company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cleo Diagnostics Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.34 |
| 52 Week High | AU$0.48 |
| 52 Week Low | AU$0.14 |
| Beta | 0 |
| 11 Month Change | -1.43% |
| 3 Month Change | -1.43% |
| 1 Year Change | 81.58% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 72.50% |
Recent News & Updates
Shareholder Returns
| COV | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -6.8% | 0.5% | 1.5% |
| 1Y | 81.6% | 14.2% | 17.2% |
Return vs Industry: COV exceeded the Australian Medical Equipment industry which returned 14.2% over the past year.
Return vs Market: COV exceeded the Australian Market which returned 17.2% over the past year.
Price Volatility
| COV volatility | |
|---|---|
| COV Average Weekly Movement | 8.7% |
| Medical Equipment Industry Average Movement | 9.1% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: COV has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: COV's weekly volatility has decreased from 14% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Richard Allman | www.cleodx.com |
Cleo Diagnostics Ltd, a medical diagnostics and devices company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company provides CleoDX pre-surgical triage tests which measures a combination of biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property and patents.
Cleo Diagnostics Ltd Fundamentals Summary
| COV fundamental statistics | |
|---|---|
| Market cap | AU$44.98m |
| Earnings (TTM) | -AU$3.76m |
| Revenue (TTM) | AU$210.81k |
210.3x
P/S Ratio-11.8x
P/E RatioIs COV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COV income statement (TTM) | |
|---|---|
| Revenue | AU$210.81k |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$210.81k |
| Other Expenses | AU$3.97m |
| Earnings | -AU$3.76m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.029 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,783.22% |
| Debt/Equity Ratio | 0% |
How did COV perform over the long term?
See historical performance and comparison